Menin disruption represents more than twenty years of preclinical work and appears to have the strongest rationale in KMT2A rearranged AML but may hold additional potential in NPM1 mutated AML and even FLT3-ITD patients. The gene discussed is FLT3; the disease is acute myeloid leukemia.